Caprock Group LLC Acquires 11,167 Shares of Medtronic PLC $MDT

Caprock Group LLC grew its holdings in shares of Medtronic PLC (NYSE:MDT) by 16.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 80,968 shares of the medical technology company’s stock after acquiring an additional 11,167 shares during the period. Caprock Group LLC’s holdings in Medtronic were worth $7,837,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the business. State Street Corp raised its stake in shares of Medtronic by 1.0% during the third quarter. State Street Corp now owns 60,460,537 shares of the medical technology company’s stock valued at $5,800,550,000 after acquiring an additional 625,992 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Medtronic by 0.9% during the third quarter. Bank of New York Mellon Corp now owns 21,468,260 shares of the medical technology company’s stock worth $2,044,637,000 after buying an additional 192,410 shares during the period. Massachusetts Financial Services Co. MA increased its position in shares of Medtronic by 0.5% during the third quarter. Massachusetts Financial Services Co. MA now owns 21,086,499 shares of the medical technology company’s stock worth $2,008,278,000 after buying an additional 98,220 shares during the period. Raymond James Financial Inc. increased its position in shares of Medtronic by 3.0% during the third quarter. Raymond James Financial Inc. now owns 11,203,865 shares of the medical technology company’s stock worth $1,067,055,000 after buying an additional 327,899 shares during the period. Finally, Wellington Management Group LLP increased its position in shares of Medtronic by 35.3% during the third quarter. Wellington Management Group LLP now owns 10,189,586 shares of the medical technology company’s stock worth $970,456,000 after buying an additional 2,658,981 shares during the period. Institutional investors own 82.06% of the company’s stock.

Medtronic Trading Up 1.5%

NYSE:MDT opened at $83.23 on Thursday. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $106.86 billion, a price-to-earnings ratio of 23.18, a PEG ratio of 2.13 and a beta of 0.75. The firm has a fifty day simple moving average of $90.44 and a two-hundred day simple moving average of $95.44. Medtronic PLC has a 12 month low of $79.93 and a 12 month high of $106.33.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The business had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The business’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period last year, the company posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts expect that Medtronic PLC will post 5.57 EPS for the current fiscal year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were issued a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 3.4%. The ex-dividend date was Friday, March 27th. Medtronic’s dividend payout ratio (DPR) is presently 79.11%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Leerink Partners reiterated an “outperform” rating and set a $119.00 price objective on shares of Medtronic in a research report on Tuesday, March 10th. Mizuho decreased their price objective on shares of Medtronic from $125.00 to $120.00 and set an “outperform” rating for the company in a research report on Monday, April 13th. Wells Fargo & Company assumed coverage on shares of Medtronic in a research report on Friday, January 30th. They set an “overweight” rating and a $114.00 price objective for the company. Stifel Nicolaus decreased their price objective on shares of Medtronic from $105.00 to $95.00 and set a “hold” rating for the company in a research report on Monday, April 6th. Finally, Daiwa Securities Group decreased their price objective on shares of Medtronic from $117.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Fifteen investment analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $108.55.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: CathWorks acquisition closed and AI coronary diagnostics bolstering Medtronic’s cardiovascular software/hardware stack — expands addressable market and recurring‑revenue potential. Medtronic Expands AI Heart Care As Investors Weigh Valuation And Momentum
• Positive Sentiment: Led a $100M investment in Pulnovo plus a commercial agreement to broaden therapies/commercialisation for cardio and hypertension treatments — shows active dealmaking to extend product pipeline and global reach. Medtronic leads $100M investment in Pulnovo Medical
• Positive Sentiment: New product momentum — Altaviva™ implant publicity (Edison Award) and first clinical use of the Stealth AXiS Autopilot robotic platform signal commercialization progress and potential future device sales. Medtronic (MDT) Valuation Check As New GE HealthCare Tie Up And Altaviva Launch Draw Investor Interest First surgeons use Medtronic Stealth AXiS Autopilot surgical robotic platform
• Neutral Sentiment: Company says CathWorks deal will be immaterial to FY2027 earnings and neutral-to-accretive in later years — suggests benefits are longer‑term rather than immediate. Medtronic concludes CathWorks’ acquisition for $585m
• Neutral Sentiment: Industry reports (wearable injectors market) cite Medtronic among players in growing home‑health/wearables opportunity — supportive for long-term addressable market but not an immediate revenue catalyst. Wearable Injectors Market Report 2026
• Negative Sentiment: UBS cut its price target from $104 to $90 and set a neutral rating — analyst downgrade and lower target add near‑term selling pressure and feed valuation worries. UBS lowers Medtronic price target
• Negative Sentiment: Recent coverage highlights share‑price weakness and YTD declines, reflecting investor concern over momentum and valuation despite product/AI catalysts. Is It Time To Reconsider Medtronic (MDT) After Recent Share Price Weakness?

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the sale, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.26% of the company’s stock.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).